tiprankstipranks
Comprehensive Healthcare Systems Inc (TSE:CHS)
:CHS
Canadian Market

Comprehensive Healthcare Systems Inc (CHS) AI Stock Analysis

3 Followers

Top Page

TSE:CHS

Comprehensive Healthcare Systems Inc

(CHS)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 5.2)
Rating:53Neutral
Price Target:
C$0.77
▲(32.93% Upside)
Action:ReiteratedDate:01/16/26
The score is held down primarily by high financial risk—deeply negative equity, ongoing net losses, and TTM cash burn—despite clear improvement in revenue scale and gross margin. Technicals are supportive with price above major moving averages and positive MACD, but overbought RSI/Stoch conditions temper the outlook. Valuation adds limited support given the negative P/E and no dividend yield provided.
Positive Factors
Revenue Growth
Sustained multi-year revenue acceleration (TTM ~3.49x vs prior year) indicates the company is scaling demand and market penetration in healthcare information services. Higher recurring revenue scale supports operational leverage and creates a larger base to absorb SG&A, improving long-term viability.
Negative Factors
Negative Equity / Weak Balance Sheet
Deeply negative equity signals an impaired capital structure and limited financial flexibility. Over 2–6 months this raises refinancing and dilution risk, constrains ability to pursue M&A or product investment, and increases dependence on external funding to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi-year revenue acceleration (TTM ~3.49x vs prior year) indicates the company is scaling demand and market penetration in healthcare information services. Higher recurring revenue scale supports operational leverage and creates a larger base to absorb SG&A, improving long-term viability.
Read all positive factors

Comprehensive Healthcare Systems Inc (CHS) vs. iShares MSCI Canada ETF (EWC)

Comprehensive Healthcare Systems Inc Business Overview & Revenue Model

Company Description
Comprehensive Healthcare Systems Inc. develops customized healthcare administrative software solutions. It offers membership cards, disease management, pre-certification, claim processing, and bill payment services. The company also provides licen...
How the Company Makes Money
CHS generates revenue primarily through the sale of its healthcare management software and electronic health records solutions. These products are offered to healthcare providers, hospitals, and clinics on a subscription or licensing basis, provid...

Comprehensive Healthcare Systems Inc Financial Statement Overview

Summary
Revenue and gross margin improved materially (TTM revenue up ~3.49x vs prior annual period; gross margin ~61%), but the business remains unprofitable with negative EBIT/EBITDA and a sizable net loss (~-27% net margin TTM). The balance sheet is a major weakness with deeply negative stockholders’ equity, and cash flow quality is inconsistent with TTM returning to negative operating cash flow and negative free cash flow.
Income Statement
28
Negative
Balance Sheet
12
Very Negative
Cash Flow
22
Negative
BreakdownTTMMar 2025Sep 2024Mar 2023Mar 2022Jan 2021
Income Statement
Total Revenue4.16M3.77M3.84M4.30M4.50M4.74M
Gross Profit2.53M2.06M1.15M1.40M1.37M2.07M
EBITDA-696.93K121.99K-2.86M-5.13M-2.63M-331.13K
Net Income-1.13M-607.73K-3.58M-5.11M-4.93M-63.14K
Balance Sheet
Total Assets885.15K938.55K1.28M2.11M4.11M276.08K
Cash, Cash Equivalents and Short-Term Investments21.78K11.03K31.55K542.64K3.40M264.35K
Total Debt2.48M3.59M3.28M1.96M2.22M3.80M
Total Liabilities6.27M10.19M9.01M5.26M3.50M11.88K
Stockholders Equity-5.39M-9.25M-7.73M-3.15M602.59K264.21K
Cash Flow
Free Cash Flow-498.27K36.31K-1.23M-4.04M-3.28M-65.05K
Operating Cash Flow-297.81K366.80K-1.23M-3.97M-3.27M-58.85K
Investing Cash Flow-518.63K-628.01K0.00-68.41K215.14K-11.73K
Financing Cash Flow824.22K245.07K852.45K1.04M4.39M3.44M

Comprehensive Healthcare Systems Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
C$436.30M90.722.75%59.34%-23.48%
53
Neutral
C$12.38M-11.5716.04%-455.38%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
C$50.98M-2.31-207.53%7.04%
45
Neutral
C$33.11M-9.483086.87%-48.53%-9.66%
42
Neutral
C$9.93M-5.126239.15%48.94%
C$10.28M-21.40527.45%-67.11%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:CHS
Comprehensive Healthcare Systems Inc
0.79
0.39
97.50%
TSE:ADK
Diagnos
0.28
<0.01
1.85%
TSE:VHI
Vitalhub
6.97
-2.73
-28.14%
TSE:AIDR
Rocket Doctor AI
0.59
0.17
40.48%
TSE:UDOC
UniDoc Health Corp
0.10
-0.22
-69.35%
TSE:DMED
DiagnaMed Holdings Corp.
0.10
0.08
300.00%

Comprehensive Healthcare Systems Inc Corporate Events

Business Operations and StrategyFinancial Disclosures
Comprehensive Healthcare Systems Hires RedChip to Lead Investor Relations and Boost Market Visibility
Positive
Jan 13, 2026
Comprehensive Healthcare Systems Inc. has engaged RedChip Companies to lead its investor relations and strategic communications, reflecting the company&#8217;s drive to broaden its visibility among institutional and retail investors as it reports ...
Business Operations and StrategyPrivate Placements and Financing
Comprehensive Healthcare Systems to Raise Up to $3.5 Million and Settle Debt Through Share Issuance
Positive
Jan 9, 2026
Comprehensive Healthcare Systems Inc. announced a non-brokered private placement of up to 7 million units at $0.50 per unit to raise as much as $3.5 million, with each unit comprising one common share and half a warrant exercisable at $1.00 for th...
Business Operations and StrategyFinancial Disclosures
Comprehensive Healthcare Systems Wins 5-Year Benefits Platform Deal with Amalgamated Life
Positive
Dec 18, 2025
Comprehensive Healthcare Systems Inc. has signed a five-year agreement with Amalgamated Employee Benefits Administrators and Amalgamated Life Insurance Company to deploy its Novus360 administration platform across Amalgamated&#8217;s pension and e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 16, 2026